Looking toward dividend payers is a particularly good idea, because companies that consistently increase their payouts tend ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming ...

Amgen Inc. (NASDAQ:AMGN) is included among the 15 Blue Chip Dividend Stocks to Build a Passive Income Porfolio. On December 3 ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amgen Inc. stock has reached a new 52-week high, hitting $345.95, marking a significant milestone for the biotechnology company. The stock is now trading just 0.99% from its 52-week high of $345.84.

Amgen Inc. (NASDAQ:AMGN) ranks among the Best Low Volatility Investments in December 2025. Goldman Sachs reaffirmed its $400 ...

Amgen (AMGN) just received full approval from the FDA for IMDELLTRA in treating adult patients with extensive stage small ...

The next-generation “GLP-1 plus” drugs will be tailored to the health needs of individual patients.

Ozempic, and the class of weight loss drugs it has come to embody, has left its imprint seemingly everywhere: On the lives of millions of patients who’ve lost unprecedented amounts of weight. On ...

Amgen is performing well despite some headwinds, and its pipeline is progressing. Gilead Sciences' strong core franchise and diversification efforts should work wonders. Both biotechs have ...